Investor Presentation for the quarter and year ended 31st March, 2026.
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kwality Pharmaceuticals reported strong FY26 results with revenue at ₹503 Cr (up 36% YoY) and net profit at ₹67 Cr (up 72% YoY). The company achieved 49% gross margin and 24% EBITDA margin, with PAT margin expanding to 14%. Management targets ₹650 Cr revenue, ₹160 Cr EBITDA (25% margin), and ₹100 Cr PAT for FY27, implying 30-35% topline growth. Four of five manufacturing units are EU-GMP approved, enabling greater access to regulated markets. The company is expanding into high-margin segments including biologics (EPO biosimilar targeting H1 FY27 launch), oncology, and hormones (Unit 6 under construction). Capex of ₹70 Cr planned for FY26 and ₹40 Cr each for FY27-28 will fund expansion across biologics, oncology, and hormones.
The company demonstrated strong execution with profit growing ~3x faster than revenue, signaling operational leverage. Management's explicit guidance for 300 bps EBITDA margin improvement to 25% by FY27 and the upcoming biologic commercialization represent significant growth catalysts that could support re-rating of the stock.